Pharmacologic characterization of FR172516: A new combined calcium channel-blocking and β-adrenoceptor-blocking agent

Journal of Cardiovascular Pharmacology

Volumn 33, Issue 4, 1999, Pages 587-594

  Yamamoto, Nobuhiro ^a   Nomura, Masahiko ^b   Okubo, Kazumi ^a   Maeda, Kazuhiro ^a   Goto, Toshio ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Blocker; Amlodipine; Antihypertensive; Calcium antagonists; FR172516; Plasma renin activity

Indexed keywords

1,4 DIHYDRO 4 [2 [4 [2 HYDROXY 3 (2 METHYLPHENOXY)PROPYLAMINO]BUTOXY] 5 NITROPHENYL] 2 METHYL 6 TRIFLUOROMETHYL 3,5 PYRIDINEDICARBOXYLIC ACID DIMETHYL ESTER; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; ISOPRENALINE; METOPROLOL; PROPRANOLOL; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CALCIUM ANTAGONISM; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFECT; DRUG STRUCTURE; FEMALE; HEART RATE; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; LIGAND BINDING; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIES; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; DOGS; HYPERTENSION, RENAL; MALE; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SWINE; TIME FACTORS; VASOCONSTRICTION;

EID: 0032940764     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199904000-00011     Document Type: Article

References (28)

1. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med 1995;155:829-37.
2. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-5.
3. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31.
4. Packer M. Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure. Circulation 1989;80(suppl IV):IV59-67.
5. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure: Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996;335:1107-14.
6. Packer M, Nicod P, Khandheria BR, et al. Randomized, multicenter, double-blind, placebo-controlled evaluation of amlodipine in patients with mild-to-moderate heart failure. J Am Coll Cardiol 1991;17:274A.
7. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J. β-Blockers and sudden cardiac death. Ann Intern Med 1995;123:358-67.
8. Olsson G, Tuomilehto J, Berglund G, et al. Primary prevention of sudden cardiovascular death in hypertensive patients: mortality results from MAPHY study. Am J Hypertens 1991;4:151-8.
9. 1-adrenoceptor blocking agent. J Pharmacol Exp Ther 1990;54:204-11.
10. 1-adrenoceptor blocking agent in rats and dogs. J Cardiovasc Pharmacol 1993;22:247-52.
11. 1-adrenoceptor blocking activity. Arch Int Pharmacodyn Ther 1994;328:213-24.
12. 3H] nitrendipine to membranes from coronary arteries and heart in relation to pharmacological effects: paradoxical stimulation by diltiazem. Biochem Biophys Res Commun 1982;108:110-7.
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;93:265-75.
14. 50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-108.
15. Kudo Y, Sokabe H, Zehr JE. A simple method to determine the ratio of cardiac to vascular β-receptor blockade in the rat in vivo. J Pharm Dyn 1981;4:475-82.
16. Truett AA, West DB. Validation of a radiotelemetry system for continuous blood pressure and heart rate monitoring in dogs. Lab Anim Sci 1995;45:299-302.
17. Bazil MK, Webb RL. Hemodynamic effects of amlodipine and benazeprilat in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1993;21:405-11.
18. Stopher DA, Beresford AP, Macrae PV, Humphrey MJ. The metabolism and pharmacokinetics of amlodipine in humans and animals. J Cardiovasc Pharmacol 1988;12(suppl 7):S55-9.
19. Schricker K, Hamann M, Macher A, Kramer BK, Kaissling B, Kutz A. Effect of amlodipine on renin secretion and renin gene expression in rats. Br J Pharmacol 1996;119:744-50.
20. Hackenthal E, Paul M, Ganten D, Taugner R. Morphology, physiology and molecular biology of renin secretion. Physiol Rev 1990;70:1067-116.
21. Koch-Wester J. Vasodilator drugs in the treatment of hypertension. Arch Intern Med 1974;133:1017-27.
22. Pettinger WA, Mitchell HC. Side-effects of vasodilator therapy. Hypertension 1988;11(suppl II):II34-6.
23. Tkacs NC, Kim M, Denzon M, Hargrave B, Ganong WF. Pharmacological evidence for involvement of the sympathetic nervous system in the increase in renin secretion produced by a low sodium diet in rats. Life Sci 1990;47:2317-22.
24. 2+ antagonist (nifedipine) in hypertensive patients. Jpn Heart J 1976;17:479-84.
25. Karasawa A, Kubo K, Shuto K, Oka T, Nakamizo N. Antihypertensive effects of the new calcium antagonist benidipine hydrochloride in rats. Arzneimittelforschung 1988;38:1684-90.
26. Letizia C, De-Ciocchis A, Cerci S, et al. Amlodipine in ambulatory hypertensive patients: humoral and hemodynamic effects. Int J Clin Pharmacol Res 1993;13:151-9.
27. Licata G, Scaglione R, Ganguzza A, et al. Effect of amlodipine on renal hemodynamics in mild and moderate hypertensive patients: a randomized controlled study versus placebo. Eur J Clin Pharmacol 1993;45:307-11.
28. Cappuccio FP, Markandu ND, Sagnela GA, et al. Effects of amlodipine on urinary sodium excretion, renin-angiotensin-aldosterone system, atrial natriuretic peptide and blood pressure in essential hypertension. J Hum Hypertens 1991;5:115-9.